Safety and Immunogenicity of a Single Dose of BNT162b2 COVID-19 mRNA Vaccine in a Warfarin-Treated Protein S Deficient Patient: A Case Report and Literature Review

Safety and Immunogenicity of a Single Dose of BNT162b2 COVID-19 mRNA Vaccine in a Warfarin-Treated Protein S Deficient Patient: A Case Report and Literature Review

Patients with protein S (PS) deficiency possibly have a higher risk of developing severe COVID-19 disease. Therefore, vaccination against SARS-CoV-2 infections is recommended for PS-deficient patients. However, there are limited data regarding the safety and immunogenicity of the currently available...

Full description

Bibliographic Details
Main Authors: Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Hematology Reports
Subjects:
COVID-19
vaccination
BNT162b2
antibody
protein S deficiency
Online Access:https://www.mdpi.com/2038-8330/14/4/51

Internet

https://www.mdpi.com/2038-8330/14/4/51

Similar Items